Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Leases Finished Goods Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Dna X (SONM) Liabilities from Discontinued Operations (2024 - 2025)

Dna X filings provide 2 years of Liabilities from Discontinued Operations readings, the most recent being 38057000.0 for Q4 2025.

On a quarterly basis, Liabilities from Discontinued Operations fell 10.98% to 38057000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 38057000.0, a 10.98% decrease, with the full-year FY2025 number at 38057000.0, down 10.98% from a year prior.
Liabilities from Discontinued Operations hit 38057000.0 in Q4 2025 for Dna X, down from 42752000.0 in the prior quarter.
In the past five years, Liabilities from Discontinued Operations ranged from a high of 42752000.0 in Q4 2024 to a low of 38057000.0 in Q4 2025.